Skip to Main content Skip to Navigation
Poster communications

Mesenchymal Stromal Cells (MSC) : phenotypical and functional characterizations as tools for immunomodulation in Myasthenia Gravis

Abstract : Several autoimmune diseases are mediated by antibodies produced after deregulations of the immune system and directed against self antigens. Myasthenia Gravis (MG) is a rare disease in which pathogenicity is due to autoantibodies directed against the neuromuscular endplate. MG is not really cured, corticosteroids and azathioprin are commonly used, however they trigger severe side-effects, mandating the setup of novel therapies. Mesenchymal Stromal/Stem Cells (MSC) are multipotent progenitor cells that can be isolated from various human tissues and can modulate the immune system via soluble mediators and cell-cell contacts. Our team has recently validated a new animal model of MG, in which we demonstrated that the transfer of MSC conditioned by peripheral blood mononucleated cells (PBMC) improved the clinical status of the animals (Sudres et al., JCI Insight 2017). To develop this immunomodulating approach in clinical perspective, we compared the phenotypes of research-grade (RG) and clinical-grade (CG) MSC testing a series of 60 antibodies (Ab) directed against surface antigens by flow cytometry. We evaluated the variations introduced by different conditioning treatments (activation by gamma-interferon, cross-stimulation by PBMC or monocytes). Markers involved in immunomodulation (recognition, activation, function of complement, co-stimulation, immune checkpoints) were increased or decreased depending on treatment. Adhesion molecules and receptors were also differentially modified (integrins, selectins, cell-cell adhesion molecules, growth factor receptors, tetraspanins). These results suggest that the conditioning regimens act through different pathways. From this panel, we derived a second one of 31 Ab allowing simultaneous labeling of MSC at single cell level by mass cytometry (CyTOF). We defined MSC clusters which were modulated upon activation. In parallel, we evaluated the functional activity of resting or conditioned CG MSC through a cell proliferation assay, and through the quantification by ELISA of secreted immunomodulating products. The conditioning regimens differentially modulated the secretion of Prostaglandin E2 and TGFbeta1, and inhibited PBMC proliferation. This work unveiled phenotypic and functional markers of MSC along with their modulations according to different treatments, and will contribute to validate a cell therapy product for immunomodulation purposes.
Document type :
Poster communications
Complete list of metadatas

https://hal.archives-ouvertes.fr/hal-02365018
Contributor : Jean-Thomas Vilquin <>
Submitted on : Wednesday, December 4, 2019 - 5:50:14 PM
Last modification on : Friday, December 11, 2020 - 3:49:40 AM
Long-term archiving on: : Thursday, March 5, 2020 - 12:23:10 PM

Files

SFI 2019 Nantes Alexandra Baye...
Files produced by the author(s)

Identifiers

  • HAL Id : hal-02365018, version 1

Citation

Alexandra Bayer Wildberger, José Villegas, Julien Verdier, Mariette Giannini, Solène Maillard, et al.. Mesenchymal Stromal Cells (MSC) : phenotypical and functional characterizations as tools for immunomodulation in Myasthenia Gravis. Myology 2019, Mar 2019, Bordeaux, France. ⟨hal-02365018⟩

Share

Metrics

Record views

61

Files downloads

58